17a-Hydroxyprogesteronecaproate , 98% , 630-56-8

Synonym(s):
17α-Hydroxyprogesterone caproate;17α-Hydroxyprogesterone hexanoate

CAS NO.：630-56-8

Empirical Formula: C27H40O4

Molecular Weight: 428.6

MDL number: MFCD00072134

EINECS: 211-138-8

PRODUCT Properties

• Melting point: 119°C
• Boiling point: 463.43°C (rough estimate)
• alpha: +44～+50°(D/20℃)(c=1,CH3OH)
• Density: 1.0148 (rough estimate)
• refractive index: 1.4840 (estimate)
• storage temp.: Sealed in dry,Room Temperature
• solubility: Chloroform (Slightly), Methanol (Slightly)
• form: Solid
• color: Off-White
• Merck: 4839
• InChIKey: DOMWKUIIPQCAJU-LJHIYBGHSA-N
• SMILES: C1(=O)C=C2[C@](C)(CC1)[C@]1([H])[C@]([H])([C@@]3([H])[C@@](CC1)(C)[C@@](OC(=O)CCCCC)(C(=O)C)CC3)CC2

Description and Uses

Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999. The U.S. FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy.

Hydroxyprogesterone Caproate is a synthetic progestin that reduces the chances of pre-term birth in women and improves specific fetal outcomes.

Safety

• Symbol(GHS): GHS08
• Signal word: Danger
• Hazard statements: H360
• Precautionary statements: P201-P202-P280-P308+P313-P405-P501
• Hazard Codes: T
• Risk Statements: 61
• Safety Statements: 53-22-36/37/39-45
• WGK Germany: 3
• RTECS: TU5085000
• HS Code: 2937230000